Background: Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced
(BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly …

Background: Previously considered inoperable patients (borderline resectable, locally
advanced, synchronous oligometastatic or metachronous pancreatic adenocarcinoma …

Advanced molecular imaging has come to play an integral role in the management of gastro-
entero-pancreatic neuroendocrine neoplasms (GEP-NENs). Somatostatin receptor (SSTR) …

Background En bloc celiac axis resection (CAR) for pancreatic cancer is considered
increasingly after modern neoadjuvant chemotherapy (NAC). Appleby and distal …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis,
mainly due to difficulty in early detection of the disease by current imaging modalities. In this …

Background Neoadjuvant therapy may improve survival of patients with pancreatic
adenocarcinoma; however, determining response to therapy is difficult. Artificial intelligence …

Background Restaging of locally advanced pancreatic cancer (LAPC) after induction
chemotherapy using contrast-enhanced computed tomography (CE-CT) imaging is …

Advances in translational imaging research coupled with progress in imaging technology
have led to a wider adoption of cross-sectional imaging for the evaluation and management …

Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease prone to
widespread metastatic dissemination and characterized by a desmoplastic stroma that …

This article gives an overview of current clinical indications, the opportunities, and the
challenges of integrated hybrid PET/magnetic resonance (MR) imaging of abdominal and …